[Research progress in drug therapy for bronchopulmonary dysplasia in preterm infants]

Area of Science:

• Neonatal Medicine
• Pediatric Pulmonology
• Pharmacology

Background:

• Bronchopulmonary dysplasia (BPD) is the most frequent chronic lung disease in extremely preterm infants.
• BPD is associated with significant morbidities, including pulmonary hypertension, increased mortality, and neurodevelopmental abnormalities.
• Current therapeutic strategies for BPD remain a subject of ongoing debate.

Purpose of the Study:

• To review the current research progress in drug therapy for BPD.
• To critically evaluate the efficacy, advantages, and disadvantages of various pharmacological interventions for BPD.
• To provide an overview of the evolving landscape of BPD pharmacotherapy.

Main Methods:

• Systematic review of existing literature on BPD drug therapy.
• Analysis of research studies focusing on pharmacological treatments for preterm infants with BPD.
• Synthesis of evidence regarding the outcomes of different drug interventions.

Main Results:

• The review highlights ongoing controversies regarding the optimal drug therapy for BPD.
• Specific drug classes and their impact on BPD progression and outcomes are discussed.
• Evidence for the efficacy and potential adverse effects of various treatments is presented.

Conclusions:

• Further research is needed to establish definitive guidelines for BPD pharmacotherapy.
• Personalized treatment approaches may be necessary given the heterogeneity of BPD.
• Optimizing drug therapy is crucial for improving long-term outcomes in infants with BPD.